51.41
2.74%
1.37
After Hours:
51.60
0.19
+0.37%
Biohaven Ltd stock is traded at $51.41, with a volume of 483.62K.
It is up +2.74% in the last 24 hours and up +7.94% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$50.04
Open:
$49.81
24h Volume:
483.62K
Relative Volume:
0.51
Market Cap:
$5.05B
Revenue:
-
Net Income/Loss:
$-746.61M
P/E Ratio:
-6.8822
EPS:
-7.47
Net Cash Flow:
$-485.24M
1W Performance:
+0.90%
1M Performance:
+7.94%
6M Performance:
+26.35%
1Y Performance:
+66.81%
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-16-24 | Initiated | Jefferies | Buy |
Sep-04-24 | Initiated | Bernstein | Outperform |
Jul-24-24 | Initiated | Morgan Stanley | Overweight |
Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
Feb-06-24 | Initiated | UBS | Buy |
Dec-22-23 | Initiated | H.C. Wainwright | Buy |
Dec-08-23 | Initiated | Robert W. Baird | Outperform |
Jan-24-23 | Initiated | SVB Securities | Outperform |
Jan-04-23 | Initiated | JP Morgan | Overweight |
Dec-02-22 | Initiated | BTIG Research | Buy |
Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Oct-12-22 | Initiated | Piper Sandler | Overweight |
Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
Aug-10-21 | Downgrade | UBS | Buy → Neutral |
Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
Mar-11-21 | Initiated | UBS | Buy |
Dec-15-20 | Initiated | H.C. Wainwright | Buy |
Apr-17-20 | Initiated | Cowen | Outperform |
Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
Feb-06-20 | Initiated | Mizuho | Buy |
Nov-22-19 | Initiated | Wedbush | Outperform |
Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
May-06-19 | Initiated | Goldman | Buy |
Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mar-04-19 | Reiterated | Needham | Buy |
Jul-03-18 | Reiterated | Needham | Buy |
Jul-02-18 | Reiterated | Needham | Buy |
Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
Dec-15-17 | Initiated | Canaccord Genuity | Buy |
Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Vanguard Group Inc's Strategic Acquisition in Biohaven Ltd - GuruFocus.com
(BHVN) Technical Data - Stock Traders Daily
Cadent Capital Advisors LLC Invests $1.77 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
(BHVN) Trading Advice - Stock Traders Daily
Scholar Rock stock could benefit from Biohaven's Ph3 results, Truist raises potential rally outlook - Investing.com India
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside By Investing.com - Investing.com South Africa
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside - Investing.com UK
Biohaven Ltd. (NYSE:BHVN) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by AQR Capital Management LLC - MarketBeat
(BHVN) Investment Analysis - Stock Traders Daily
17,064 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by Squarepoint Ops LLC - MarketBeat
Biohaven retains Outperform stock rating on clinical results By Investing.com - Investing.com South Africa
Biohaven holds steady with $60 target on SMA trial optimism - Investing.com India
Biohaven holds steady with $60 target on SMA trial optimism By Investing.com - Investing.com Australia
Biohaven maintains Buy rating with $59 target amid SMA trial optimism By Investing.com - Investing.com South Africa
Biohaven (NYSE:BHVN) Stock Price Up 4.9%Here's What Happened - MarketBeat
Vladimir Coric Buys Handful Of Shares In Biohaven - Simply Wall St
Biohaven Stock Soars on Drug Trial Results: Time to Jump In? - MSN
Cantor Fitzgerald Reiterates "Overweight" Rating for Biohaven (NYSE:BHVN) - MarketBeat
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - MSN
Analysts’ Recent Ratings Changes for Biohaven (BHVN) - Defense World
Biohaven (NYSE:BHVN) Price Target Raised to $68.00 at JPMorgan Chase & Co. - MarketBeat
Biohaven (NYSE:BHVN) Shares Gap Up After Insider Buying Activity - MarketBeat
John W. Childs Purchases 21,052 Shares of Biohaven Ltd. (NYSE:BHVN) Stock - Defense World
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock - Yahoo Finance
Biohaven director Childs buys shares worth nearly $1 million By Investing.com - Investing.com South Africa
Biohaven CEO Vlad Coric acquires $999,970 in company stock By Investing.com - Investing.com Australia
Biohaven director Childs buys shares worth nearly $1 million - Investing.com
Biohaven CEO Vlad Coric acquires $999,970 in company stock - Investing.com India
Marshall Wace LLP Sells 677,724 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Lelezard.com
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Biohaven sets public offering price at $47.50 per share By Investing.com - Investing.com Australia
Biohaven shares could see growth as MDD and bipolar studies advance, per TD Cowen - Investing.com India
Biohaven (NYSE:BHVN) Sees Strong Trading Volume - MarketBeat
Biohaven sets public offering price at $47.50 per share - Investing.com
Biohaven down after $250 mln stock offering prices - XM
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - Nasdaq
Biohaven launches $250 million public stock offering By Investing.com - Investing.com Australia
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust By Investing.com - Investing.com South Africa
Biohaven launches $250 million public stock offering - Investing.com India
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust - Investing.com India
Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire
Biohaven starts phase 2 trial for new migraine treatment - Investing.com India
Biohaven starts phase 2 trial for new migraine treatment By Investing.com - Investing.com UK
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - PR Newswire
Driehaus Capital Management LLC Lowers Stake in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Indo-Asian News Service - IANS India Pvt Ltd
Biohaven, Tesla And Other Big Stocks Moving Higher On Monday - MSN
97,902 Shares in Biohaven Ltd. (NYSE:BHVN) Purchased by Cubist Systematic Strategies LLC - Defense World
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):